MedTrace Logo

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs

NCT00675207 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2008-05-08

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Brimonidine purite 0.15%

A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.

DRUG

Dorzolamide 2%

A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.

DRUG

Brinzolamide 1%

A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.

Sponsors & Collaborators

  • Research to Prevent Blindness

    collaborator OTHER

  • Northwestern Ophthalmic Institute S.C.

    lead OTHER

Principal Investigators

  • Thomas E. Bournias, MD · Northwestern Ophthalmic Institute S.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675207 on ClinicalTrials.gov